A<unk>  is a<unk>  for<unk> , defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many<unk> s combine several<unk>  drugs in combination<unk> . The majority of drugs used in cancer<unk>  are cytostatic, many via cytotoxicity. A fundamental philosophy of medical oncology, including combination<unk> , is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in<unk> s. The first successful combination<unk>  was MOPP, introduced in 1963 for lymphomas. The term "induction<unk> " refers to a<unk>  used for the initial treatment of a disease. A "maintenance<unk> " refers to the ongoing use of<unk>  to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.<unk> s are often identified by acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across<unk> s, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments. There is no widely accepted naming convention or standard for the nomenclature of<unk> s. For example, either generic or brand names may be used for acronyms. This page merely lists commonly used conventions.
Chemotherapy regimen
Adjuvant therapy
Hormone therapy
Hormonal therapy 
Antihormone therapy
Neoadjuvant therapy
Cervical cancer staging
Breast surgery